alfresa holdings corp (2784) Details

Alfresa Holdings Corporation, through its subsidiaries, engages in the wholesale, manufacture, marketing, and import/export of pharmaceuticals, diagnostic reagents, medical devices and equipment, and other products primarily in Japan. The company is involved in the wholesale of ethical pharmaceuticals prescribed at hospitals and clinics; diagnostic reagents, such as those used in laboratories of medical institutions; and medical devices, including X-ray machines and MRI machines. It also offers pharmaceuticals in the fields of neuropsychiatric disorders, allergy, and gastrointestinal diseases, as well as generic drugs and drugs for the treatment of rare diseases. The company primarily manufactures Tofranil 10mg and 25mg tablets for the treatment of depression, depressive disorders, and enuresis; and NESPLON Cable System, a cable used in the orthopedics field for internal spinal fixation, as well as develops Modiodal 100 mg tablets for the treatment of obstructive sleep apnea syndrome; and Tetrabenazine for the treatment of chorea accompanying Huntington’s disease. In addition, it supplies the fecal occult blood test agents and devices that enable tests for the diagnosis of colorectal cancer; and diagnostic kits, which aid rapid diagnosis of influenza virus, adenovirus, and other infectious diseases in clinical and nursing settings. Further, the company offers approximately 10,000 varieties of surgical sutures primarily for general surgery, cardiovascular surgery, and plastic surgery; and surgical tools that use microwaves and other devices. Alfresa Holdings Corporation distributes its products to medical institutions, hospitals and clinics, dispensing pharmacies, drug stores, and other customers through a network of distribution centers. The company was founded in 2003 and is headquartered in Tokyo, Japan.

alfresa holdings corp (2784) Top Compensated Officers